MXPA06011550A - Metodos para suprimir neovascularizacion utilizando ephrinb2. - Google Patents

Metodos para suprimir neovascularizacion utilizando ephrinb2.

Info

Publication number
MXPA06011550A
MXPA06011550A MXPA06011550A MXPA06011550A MXPA06011550A MX PA06011550 A MXPA06011550 A MX PA06011550A MX PA06011550 A MXPA06011550 A MX PA06011550A MX PA06011550 A MXPA06011550 A MX PA06011550A MX PA06011550 A MXPA06011550 A MX PA06011550A
Authority
MX
Mexico
Prior art keywords
methods
ephrinb2
neovascularization
suppressing neovascularization
suppressing
Prior art date
Application number
MXPA06011550A
Other languages
English (en)
Inventor
Kimihiko Fujisawa
Tatsuro Ishibashi
Yasuaki Hata
Tadahisa Kagimoto
Original Assignee
Aqumen Biopharmaceuticals K K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aqumen Biopharmaceuticals K K filed Critical Aqumen Biopharmaceuticals K K
Publication of MXPA06011550A publication Critical patent/MXPA06011550A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se proporcionan metodos para inhibir la sintesis de ADN, activacion de cinasa MAP y formacion de tubo de celulas endoteliales. Tambien se proporcionan metodos para inhibir angiogenesis y neovascularizacion, asi como composiciones utiles para los metodos aqui descritos.
MXPA06011550A 2004-04-05 2005-04-05 Metodos para suprimir neovascularizacion utilizando ephrinb2. MXPA06011550A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55899904P 2004-04-05 2004-04-05
PCT/IB2005/002634 WO2006006079A2 (en) 2004-04-05 2005-04-05 Methods for suppressing neovascularization using ephrinb2

Publications (1)

Publication Number Publication Date
MXPA06011550A true MXPA06011550A (es) 2007-06-11

Family

ID=35784236

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06011550A MXPA06011550A (es) 2004-04-05 2005-04-05 Metodos para suprimir neovascularizacion utilizando ephrinb2.

Country Status (9)

Country Link
US (1) US20090042778A1 (es)
EP (1) EP1734985A2 (es)
JP (1) JP3983271B1 (es)
CN (1) CN101151045A (es)
AU (1) AU2005261363B2 (es)
BR (1) BRPI0508202A (es)
CA (1) CA2561841A1 (es)
MX (1) MXPA06011550A (es)
WO (1) WO2006006079A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006300222A1 (en) * 2005-10-05 2007-04-19 Aqumen Biopharmaceuticals K.K. Method of inhibiting angiogenesis by using ephrin B2
JP2009221107A (ja) * 2006-05-24 2009-10-01 Aqumen Biopharmaceuticals Kk エフリンｂ２の活性を高めるペプチド，その塩，医薬用組成物，治療用キット
JP3970311B1 (ja) * 2006-09-01 2007-09-05 アキュメンバイオファーマ株式会社 新生血管阻害剤，ＤＮＡ合成阻害剤，ｐ４４／ｐ４２ＭＡＰＫリン酸化活性阻害剤及び医療用キット
US20120207743A1 (en) * 2011-02-14 2012-08-16 Allergan, Inc. Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026827A1 (en) * 2000-09-29 2002-04-04 Novartis Ag Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules

Also Published As

Publication number Publication date
CN101151045A (zh) 2008-03-26
EP1734985A2 (en) 2006-12-27
JP3983271B1 (ja) 2007-09-26
AU2005261363B2 (en) 2009-07-30
CA2561841A1 (en) 2006-01-19
US20090042778A1 (en) 2009-02-12
AU2005261363A1 (en) 2006-01-19
BRPI0508202A (pt) 2007-07-17
JP2007531708A (ja) 2007-11-08
WO2006006079A2 (en) 2006-01-19
WO2006006079A3 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
EA200601303A1 (ru) Система ретрансляторов сигнала
TW200621721A (en) Methods of preparing indazole compounds
TN2010000213A1 (en) Wise binding antibodies and epitopes
MX336807B (es) Composiciones y metodos para producir una composicion.
ATE473744T1 (de) Modifizierte pyrimidin-glucocorticoid-rezeptor- modulatoren
DK1864132T3 (da) Fra amnion stammende cellesammensætninger, fremgangsmåder til fremstilling deraf og anvendelser deraf
MX2009009773A (es) Sintesis de gamma-carbolinas fusionadas con heterociclo substituido.
WO2005118824A3 (en) Methods and compositions for the inhibition of gene expression
MX2020005214A (es) Formulaciones de anticuerpos.
TW200720232A (en) Crystalline solid forms of tigecycline and methods of preparing same
MY152068A (en) Bispecific anti-her antibodies
MY155621A (en) Axl antibodies
WO2009076676A3 (en) Compositions and methods for producing isoprene
MX2009003938A (es) Anticuerpos e inmunoconjugados y sus usos.
SG150511A1 (en) Viral polymerase inhibitors
PL2069332T3 (pl) Związki azetydynowe jako antagoniści receptorów oreksynowych
WO2011156654A3 (en) Pathways characterization of cells
TW200615272A (en) Crystalline mycophenolate sodium
WO2007014373A3 (en) Novel cells, compositions, and methods
EP1835074A4 (en) COMPOSITION FOR EARNINGS SUPPLIERS
WO2012103360A3 (en) Wnt compositions and methods of use thereof
GB2461659A (en) Structured compositions comprising a clay
MX2007010332A (es) Metodos y composiciones para promover adhesion o migracion de celula endotelial.
MY150643A (en) Methods and compositions for targeting hepsin
WO2007014250A3 (en) Abl kinase inhibition